<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 15:25:10[mciao0825] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<header>
<title>Evidence-based medicine</title>
<id>10013</id>
<revision>
<id>241735751</id>
<timestamp>2008-09-29T09:42:23Z</timestamp>
<contributor>
<username>Sz-iwbot</username>
<id>7780295</id>
</contributor>
</revision>
<categories>
<category>All NPOV disputes</category>
<category>NPOV disputes from December 2007</category>
<category>Medical informatics</category>
<category>Healthcare quality</category>
<category>Evidence-based medicine</category>
</categories>
</header>
<bdy>

<b>Evidence-based medicine</b> (EBM) aims to apply <link xlink:type="simple" xlink:href="../854/5236854.xml">
evidence</link> gained from the <link xlink:type="simple" xlink:href="../833/26833.xml">
scientific method</link> to certain parts of medical practice. It seeks to assess the quality of evidence<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref> relevant to the risks and benefits of <link xlink:type="simple" xlink:href="../819/13311819.xml">
treatments</link> (including lack of treatment). According to the Centre for Evidence-Based Medicine, "Evidence-based medicine is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients."<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref><p>

EBM recognizes that many aspects of medical care depend on individual factors such as <link xlink:type="simple" xlink:href="../789/47789.xml">
quality</link> and <link xlink:type="simple" xlink:href="../238/216238.xml">
value-of-life</link> judgments, which are only partially subject to scientific methods. EBM, however, seeks to clarify those parts of medical practice that are in principle subject to scientific methods and to apply these methods to ensure the best <it><link xlink:type="simple" xlink:href="../066/246066.xml">
prediction</link></it> of outcomes in medical treatment, even as debate about which outcomes are desirable continues.</p>
<p>

The foundation of evidence-based medicine is the <link xlink:type="simple" xlink:href="../579/2994579.xml">
systematic review</link> of evidence for particular treatments, mainly <link xlink:type="simple" xlink:href="../180/163180.xml">
randomized controlled trial</link>s. The <link xlink:type="simple" xlink:href="../721/237721.xml">
Cochrane Collaboration</link> leads this effort. A 2001 review of 160 Cochrane systematic reviews in the 1998 database revealed that, according to two readers, 41.3% concluded positive or possibly positive effect, 20% concluded evidence of no effect, 8.1% concluded net harmful effects, and 21.3% of the reviews concluded insufficient evidence.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%223%22])">3</ref> A review of 145 <link xlink:type="simple" xlink:href="../845/1845.xml">
alternative medicine</link> Cochrane reviews using the more up-to-date 2004 database revealed that 38.4% concluded positive effect or possibly positive (12.4%) effect, 4.8% concluded no effect, 0.69% concluded harmful effect, and 56.6% concluded insufficient evidence.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%224%22])">4</ref>:135-136 </p>

<sec>
<st>
Overview</st>
<p>

Using techniques from <link xlink:type="simple" xlink:href="../700/26700.xml">
science</link>, <link xlink:type="simple" xlink:href="../251/9251.xml">
engineering</link>, and <link xlink:type="simple" xlink:href="../685/26685.xml">
statistics</link>, such as <link xlink:type="simple" xlink:href="../329/62329.xml">
meta-analysis</link> of <link xlink:type="simple" xlink:href="../635/5242635.xml">
medical literature</link>, <link xlink:type="simple" xlink:href="../316/2244316.xml">
risk-benefit analysis</link>, and <link xlink:type="simple" xlink:href="../180/163180.xml">
randomized controlled trial</link>s, EBM aims for the ideal that <link xlink:type="simple" xlink:href="../925/261925.xml">
healthcare</link> professionals should make "conscientious, explicit, and judicious use of current best evidence" in their everyday practice.</p>
<p>

Generally, there are three distinct, but interdependent, areas of EBM. The first is to treat individual patients with acute or chronic pathologies by treatments supported in the most scientifically valid medical literature. Thus, medical practitioners would select treatment options for specific cases based on the best research for each patient they treat. The second area is the <link xlink:type="simple" xlink:href="../579/2994579.xml">
systematic review</link> of medical literature to evaluate the best studies on specific topics. This process can be very human-centered, as in a <link xlink:type="simple" xlink:href="../877/3089877.xml">
journal club</link>, or highly technical, using computer programs and information techniques such as <link xlink:type="simple" xlink:href="../253/42253.xml">
data mining</link>. Increased use of <link xlink:type="simple" xlink:href="../340/15340.xml">
information technology</link> turns large volumes of information into practical guides. Finally, evidence-based medicine can be understood as a medical "movement" in which advocates work to popularize the method and usefulness of the practice in the public, patient communities, educational institutions, and continuing education of practicing professionals.  </p>
<p>

Evidence-based medicine has demoted <it>ex cathedra</it> statements of the "medical <link xlink:type="simple" xlink:href="../892/9892.xml">
expert</link>" to the least valid form of evidence. All "experts" are now expected to reference their pronouncements to scientific studies.</p>

</sec>
<sec>
<st>
Classification</st>
<p>

Two types of evidence-based medicine have been proposed.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%225%22])">5</ref>
</p>
<ss1>
<st>
Evidence-based guidelines</st>
<p>

Evidence-based guidelines (EBG) is the practice of evidence-based medicine at the organizational or institutional level. This includes the production of guidelines, policy, and regulations. This approach has also been called evidence based healthcare.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%226%22])">6</ref></p>

</ss1>
<ss1>
<st>
Evidence-based individual decision making</st>
<p>

Evidence-based individual decision (EBID) making is evidence-based medicine as practiced by the individual <link xlink:type="simple" xlink:href="../110/6142110.xml">
health care provider</link>. There is concern that current evidence-based medicine focuses excessively on EBID.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%225%22])">5</ref></p>

</ss1>
</sec>
<sec>
<st>
History</st>
<p>

Although testing medical interventions for <link xlink:type="simple" xlink:href="../469/896469.xml">
efficacy</link> has existed since the time of <scholar wordnetid="110557854" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../130/1130.xml">
Avicenna</link></scholar>
's <it><work wordnetid="104599396" confidence="0.8">
<product wordnetid="104007894" confidence="0.8">
<creation wordnetid="103129123" confidence="0.8">
<artifact wordnetid="100021939" confidence="0.8">
<book wordnetid="106410904" confidence="0.8">
<publication wordnetid="106589574" confidence="0.8">
<link xlink:type="simple" xlink:href="../242/145242.xml">
The Canon of Medicine</link></publication>
</book>
</artifact>
</creation>
</product>
</work>
</it> in the 11th century,<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%227%22])">7</ref><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%228%22])">8</ref> it was only in the 20th century that this effort evolved to impact almost all fields of health care and policy. Professor <person wordnetid="100007846" confidence="0.9638700866880419">
<link xlink:type="simple" xlink:href="../718/237718.xml">
Archie Cochrane</link></person>
, a Scottish epidemiologist, through his book <it>Effectiveness and Efficiency: Random Reflections on Health Services</it> (1972) and subsequent advocacy, caused increasing acceptance of the concepts behind evidence-based practice. Cochrane's work was honoured through the naming of centres of evidence-based medical research &mdash; <it>Cochrane Centres</it> &mdash; and an international organization, the <link xlink:type="simple" xlink:href="../721/237721.xml">
Cochrane Collaboration</link>. The explicit methodologies used to determine "best evidence" were largely established by the McMaster University research group led by <physical_entity wordnetid="100001930" confidence="0.8">
<person wordnetid="100007846" confidence="0.8">
<intellectual wordnetid="109621545" confidence="0.8">
<adult wordnetid="109605289" confidence="0.8">
<health_professional wordnetid="110165109" confidence="0.8">
<scientist wordnetid="110560637" confidence="0.8">
<professional wordnetid="110480253" confidence="0.8">
<doctor wordnetid="110020890" confidence="0.8">
<medical_practitioner wordnetid="110305802" confidence="0.8">
<alumnus wordnetid="109786338" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<research_worker wordnetid="110523076" confidence="0.8">
<scholar wordnetid="110557854" confidence="0.8">
<link xlink:type="simple" xlink:href="../408/7946408.xml">
David Sackett</link></scholar>
</research_worker>
</causal_agent>
</alumnus>
</medical_practitioner>
</doctor>
</professional>
</scientist>
</health_professional>
</adult>
</intellectual>
</person>
</physical_entity>
 and <physical_entity wordnetid="100001930" confidence="0.8">
<person wordnetid="100007846" confidence="0.8">
<medical_practitioner wordnetid="110305802" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<scientist wordnetid="110560637" confidence="0.8">
<health_professional wordnetid="110165109" confidence="0.8">
<adult wordnetid="109605289" confidence="0.8">
<professional wordnetid="110480253" confidence="0.8">
<research_worker wordnetid="110523076" confidence="0.8">
<doctor wordnetid="110020890" confidence="0.8">
<link xlink:type="simple" xlink:href="../787/3860787.xml">
Gordon Guyatt</link></doctor>
</research_worker>
</professional>
</adult>
</health_professional>
</scientist>
</causal_agent>
</medical_practitioner>
</person>
</physical_entity>
. The term "evidence based" was first used in 1990 by David Eddy.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%229%22])">9</ref><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%225%22])">5</ref> The term "evidence-based medicine" first appeared in the medical literature in 1992 in a paper by Guyatt <it>et al</it>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2210%22])">10</ref></p>

</sec>
<sec>
<st>
Qualification of evidence</st>
<p>

Evidence-based medicine categorizes different types of clinical evidence and ranks them according to the strength of their freedom from the various biases that beset medical research. For example, the strongest evidence for therapeutic interventions is provided by systematic review of <link xlink:type="simple" xlink:href="../717/241717.xml">
randomized</link>, <link xlink:type="simple" xlink:href="../248/277248.xml">
double-blind</link>, <link xlink:type="simple" xlink:href="../821/142821.xml">
placebo</link>-controlled trials involving a homogeneous patient population and medical condition. In contrast, patient testimonials, case reports, and even expert opinion have little value as proof because of the placebo effect, the biases inherent in observation and reporting of cases, difficulties in ascertaining who is an expert, and more.</p>
<p>

Systems to stratify evidence by quality have been developed, such as this one by the <link xlink:type="simple" xlink:href="../109/12553109.xml">
U.S. Preventive Services Task Force</link>   for ranking evidence about the effectiveness of treatments or screening:
<list>
<entry level="1" type="bullet">

Level I: Evidence obtained from at least one properly designed <link xlink:type="simple" xlink:href="../180/163180.xml">
randomized controlled trial</link>.</entry>
<entry level="1" type="bullet">

Level II-1: Evidence obtained from well-designed controlled trials without <link xlink:type="simple" xlink:href="../462/65462.xml">
randomization</link>.</entry>
<entry level="1" type="bullet">

Level II-2: Evidence obtained from well-designed <link xlink:type="simple" xlink:href="../187/2181187.xml">
cohort</link> or <link xlink:type="simple" xlink:href="../661/788661.xml">
case-control</link> analytic studies, preferably from more than one center or research group.</entry>
<entry level="1" type="bullet">

Level II-3: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be regarded as this type of evidence.</entry>
<entry level="1" type="bullet">

Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.</entry>
</list>
</p>
<p>

The UK <link xlink:type="simple" xlink:href="../572/16462572.xml">
National Health Service</link> uses a similar system with categories labeled A, B, C, and D. The above Levels are only appropriate for treatment or interventions; different types of research are required for assessing diagnostic accuracy or natural history and prognosis, and hence different "levels" are required. For example, the Oxford Centre for Evidence-based Medicine suggests levels of evidence (LOE) according to the study designs and critical appraisal of prevention, diagnosis, prognosis, therapy, and harm studies:<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2211%22])">11</ref></p>
<p>

<list>
<entry level="1" type="bullet">

Level A: Consistent <link xlink:type="simple" xlink:href="../180/163180.xml">
Randomised Controlled Clinical Trial</link>, <link xlink:type="simple" xlink:href="../271/397271.xml">
cohort study</link>, all or none (see note below), clinical decision rule validated in different populations.</entry>
<entry level="1" type="bullet">

Level B: Consistent Retrospective Cohort, Exploratory Cohort, Ecological Study, Outcomes Research, <link xlink:type="simple" xlink:href="../661/788661.xml">
case-control study</link>; or extrapolations from level A studies.</entry>
<entry level="1" type="bullet">

Level C: <link xlink:type="simple" xlink:href="../159/11832159.xml">
Case-series study</link> or extrapolations from level B studies.</entry>
<entry level="1" type="bullet">

Level D: Expert opinion without explicit critical appraisal, or based on <link xlink:type="simple" xlink:href="../597/23597.xml">
physiology</link>, bench research or first principles.</entry>
</list>
</p>
<p>

A newer system is by the <weblink xlink:type="simple" xlink:href="http://www.gradeworkinggroup.org/">
Grade Working Group</weblink> and takes in account more dimensions that just the quality of medical evidence.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2212%22])">12</ref>
"Extrapolations" are where data is used in a situation which has potentially clinically important differences than the original study situation. Thus, the quality of evidence to support a clinical decision is a combination of the quality of research data and the clinical 'directness' of the data.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2213%22])">13</ref></p>
<p>

Despite the differences between systems, the purposes are the same: to guide users of clinical research information about which studies are likely to be most valid. However, the individual studies still require careful critical appraisal.</p>
<p>

Note: The all or none principle is met when all patients died before the Rx became available, but some now survive on it; or when some patients died before the Rx became available, but none now die on it.</p>

<ss1>
<st>
Categories of recommendations</st>

<p>

In guidelines and other publications, recommendation for a clinical service is classified by the balance of risk versus benefit of the service <it>and</it> the level of evidence on which this information is based. The <link xlink:type="simple" xlink:href="../109/12553109.xml">
U.S. Preventive Services Task Force</link> uses:<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2214%22])">14</ref>
<list>
<entry level="1" type="bullet">

Level A: Good scientific evidence suggests that the benefits of the clinical service substantially outweighs the potential risks. Clinicians should discuss the service with eligible patients. </entry>
<entry level="1" type="bullet">

Level B: At least fair scientific evidence suggests that the benefits of the clinical service outweighs the potential risks. Clinicians should discuss the service with eligible patients. </entry>
<entry level="1" type="bullet">

Level C: At least fair scientific evidence suggests that there are benefits provided by the clinical service, but the balance between benefits and risks are too close for making general recommendations. Clinicians need not offer it unless there are individual considerations. </entry>
<entry level="1" type="bullet">

Level D: At least fair scientific evidence suggests that the risks of the clinical service outweighs potential benefits. Clinicians should not routinely offer the service to asymptomatic patients. </entry>
<entry level="1" type="bullet">

Level I: Scientific evidence is lacking, of poor quality, or conflicting, such that the risk versus benefit balance cannot be assessed. Clinicians should help patients understand the uncertainty surrounding the clinical service.</entry>
</list>
</p>

</ss1>
</sec>
<sec>
<st>
Statistical measures in evidence-based medicine</st>
<p>

Evidence-based medicine attempts to express clinical benefits of tests and treatments using mathematical methods. Tools used by practitioners of evidence-based medicine include:</p>
<p>

<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../035/45035.xml">
Likelihood ratio</link>s. The <link xlink:type="simple" xlink:href="../877/472877.xml">
pretest probability</link> of a particular diagnosis, multiplied by the likelihood ratio, determines the <link xlink:type="simple" xlink:href="../672/357672.xml">
posttest probability</link>. This reflects <statement wordnetid="106722453" confidence="0.8">
<message wordnetid="106598915" confidence="0.8">
<theorem wordnetid="106752293" confidence="0.8">
<proposition wordnetid="106750804" confidence="0.8">
<link xlink:type="simple" xlink:href="../569/49569.xml">
Bayes' theorem</link></proposition>
</theorem>
</message>
</statement>
. The differences in likelihood ratio between clinical tests can be used to prioritize clinical tests according to their usefulness in a given clinical situation.</entry>
</list>
</p>
<p>

<list>
<entry level="1" type="bullet">

The area under the receiver operator characteristic curve (AUC-ROC) reflects the relationship between <link xlink:type="simple" xlink:href="../690/41690.xml">
sensitivity</link> and <link xlink:type="simple" xlink:href="../626/6945626.xml">
specificity</link> for a given test. High-quality tests will have an AUC-ROC approaching 1, and high-quality publications about clinical tests will provide information about the AUC-ROC. Cutoff values for positive and negative tests can influence specificity and sensitivity, but they do not affect AUC-ROC.</entry>
</list>
</p>
<p>

<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../571/1964571.xml">
Number needed to treat</link> or <link xlink:type="simple" xlink:href="../311/2622311.xml">
Number needed to harm</link> are ways of expressing the effectiveness and safety of an intervention in a way that is clinically meaningful. In general, NNT is always computed with respect to two treatments A and B, with A typically a drug and B a placebo (in our example above, A is a 5-year treatment with the hypothetical drug, and B is no treatment). A defined endpoint has to be specified (in our example: the appearance of colon cancer in the 5 year period). If the probabilities pA and pB of this endpoint under treatments A and B, respectively, are known, then the NNT is computed as 1/(pB-pA). The NNT for breast mammography is 1/285, so 285 mammograms need to be performed to diagnose one breast cancer. As another example, an NNT of 4 means if 4 patients are treated, only one would respond.</entry>
</list>
</p>
<p>

An NNT of 1 is the most effective and means each patient treated responds, e.g., in comparing antibiotics with placebo in the eradication of <it><substance wordnetid="100020090" confidence="0.8">
<carcinogen wordnetid="114793812" confidence="0.8">
<condition wordnetid="113920835" confidence="0.8">
<state wordnetid="100024720" confidence="0.8">
<link xlink:type="simple" xlink:href="../665/199665.xml">
Helicobacter pylori</link></state>
</condition>
</carcinogen>
</substance>
</it>. An NNT of 2 or 3 indicates that a treatment is quite effective (with one patient in 2 or 3 responding to the treatment). An NNT of 20 to 40 can still be considered clinically effective.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2215%22])">15</ref></p>

</sec>
<sec>
<st>
Quality of clinical trial publications</st>
<p>

Evidence-based medicine attempts to objectively evaluate the quality of clinical research by critically assessing techniques reported by researchers in their publications.</p>
<p>

<list>
<entry level="1" type="bullet">

Trial design considerations. High-quality studies have clearly-defined eligibility criteria, and have minimal missing data.</entry>
</list>
</p>
<p>

<list>
<entry level="1" type="bullet">

Generalizability considerations. Studies may only be applicable to narrowly-defined patient populations, and may not be generalizable to clinical practice.</entry>
</list>
</p>
<p>

<list>
<entry level="1" type="bullet">

Followup. Sufficient time for defined outcomes to occur can influence the study outcomes and the <link xlink:type="simple" xlink:href="../695/238695.xml">
statistical power</link> of a study to detect differences between a treatment and control arm.</entry>
</list>
</p>
<p>

<list>
<entry level="1" type="bullet">

Power. A mathematical calculation can determine if the number of patients is sufficient to detect a difference between treatment arms. A negative study may reflect a lack of benefit, or simply a lack of sufficient quantities of patients to detect a difference.</entry>
</list>
</p>

<ss1>
<st>
Limitations of available evidence</st>
<p>

It is recognised that not all evidence is made accessible, that this can limit the effectiveness of any approach, and that effort to reduce various publication and retrieval biases is required.</p>
<p>

Failure to publish negative trials is the most obvious gap, and moves to register all trials at the outset, and then to pursue their results, are underway. Changes in publication methods, particularly related to the Web, should reduce the difficulty of obtaining publication for a paper on a trial that concludes it did not prove anything new, including its starting hypothesis.</p>
<p>

Treatment effectiveness reported from clinical studies may be higher than that achieved in later routine clinical practice due to the closer patient monitoring during trials that leads to much higher compliance rates.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2216%22])">16</ref></p>

</ss1>
</sec>
<sec>
<st>
Effectiveness</st>
<p>

There are mixed reports about whether evidence-based medicine is effective. Using the classification scheme above --dividing evidence-based medicine into evidence-based guidelines (EBG) and evidence-based individual decision (EBID)-- may explain the conflict. It is difficult to find evidence that EBID improves health care, whereas there is growing evidence of improvements in the efficacy of health care when evidence-based medicine is practiced at the organizational level.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2217%22])">17</ref>  One of the virtues of <link xlink:type="simple" xlink:href="../359/13061359.xml">
healthcare accreditation</link> is that it offers an opportunity to assess the overall functioning of a hospital or healthcare organisation against the best of the currently-available evidence and to assist the hospital or healthcare organisation to move towards a more effective application of evidence-based medical.</p>

</sec>
<sec>
<st>
Criticism of evidence-based medicine</st>

<p>

<table class="metadata plainlinks ambox ">
<row>
<col>

ambox-content" style=""</col>
</row>
<row>
<col class="mbox-image"><p>

<image width="40px" src="Unbalanced_scales.svg">
</image>
</p>
</col>
<col style="" class="mbox-text">
 <b>The  of this section is .</b> 
Please see the discussion on the . <it>(December 2007)</it>Please do not remove this message until the </col>
</row>
</table>


Critics of EBM say lack of evidence and lack of benefit are not the same, and that the more data are pooled and aggregated, the more difficult it is to compare the patients in the studies with the patient in front of the doctor — that is, EBM applies to populations, not necessarily to individuals. In <it>The limits of evidence-based medicine</it>,<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref>Tonelli argues that "the knowledge gained from clinical research does not directly answer the primary clinical question of what is best for the patient at hand."  Tonelli suggests that proponents of evidence-based medicine discount the value of clinical experience.</p>
<p>

However, many proponents of EBM argue that the best practice of EBM does not discount clinicians' own experience. For instance David Sackett writes that "the practice of evidence based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research".<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2218%22])">18</ref></p>
<p>

Although evidence-based medicine is becoming regarded as the "<link xlink:type="simple" xlink:href="../000/723000.xml">
gold standard</link>" for clinical practice and treatment guidelines, there are a number of reasons why most current medical and surgical practices do not have a strong literature base supporting them. 
<list>
<entry level="1" type="bullet">

 In some cases, such as in open-heart surgery, conducting randomized, placebo-controlled trials would be unethical, although <link xlink:type="simple" xlink:href="../483/6326483.xml">
observational studies</link> may address these problems to some degree. </entry>
<entry level="1" type="bullet">

 Certain groups have been historically under-researched (racial minorities and people with many co-morbid diseases), and thus the literature is sparse in areas that do not allow for generalizing.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2219%22])">19</ref></entry>
<entry level="1" type="bullet">

 The types of trials considered "gold standard" (i.e. randomized double-blind placebo-controlled trials) may be expensive, so that funding sources play a role in what gets investigated. For example, public authorities may tend to fund preventive medicine studies to improve public health as a whole, while pharmaceutical companies fund studies intended to demonstrate the efficacy and safety of particular drugs.  </entry>
<entry level="1" type="bullet">

 The studies that are published in medical journals may not be representative of all the studies that are completed on a given topic (published and unpublished) or may be misleading due to conflicts of interest (i.e. <link xlink:type="simple" xlink:href="../115/511115.xml">
publication bias</link>).<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2220%22])">20</ref> Thus the array of evidence available on particular therapies may not be well-represented in the literature. A 2004 statement by the International Committee of Medical Journal Editors that they will refuse to publish clinical trial results if the trial was not recorded publicly at its outset, may help with this, although this has to date still not been actioned. </entry>
<entry level="1" type="bullet">

 The quality of studies performed varies, making it difficult to generalize about the results.</entry>
</list>
</p>
<p>

An additional problem is that large randomized controlled trials are useful for examining discrete interventions for carefully defined medical conditions. The more complex the patient population (e.g. severity of condition, co-morbid conditions, etc) in the study, the more difficult it is to assess the treatment effect (i.e., treatment mean - control group mean), relative to the random variation (within group variation of both the treatment and control groups). Because of this, a number of studies obtain non-significant results, either because there is insufficient power to show a difference, or because the groups are not well-enough "controlled". Ironically, the fewer restrictions there are on who can participate in a study (i.e., the greater the generalizability of the results to the type of patient being seen in a real world setting) the less able the study to detect real differences between groups for a given sample size.</p>
<p>

Furthermore, evidence-based <link xlink:type="simple" xlink:href="../685/1294685.xml">
guidelines</link> do not remove the problem of extrapolation to different populations or longer timeframes. Even if several top-quality studies are available, questions always remain about how far, and to which populations, their results are "generalizable". <cite id="CITEREF" style="font-style:normal"></cite>&nbsp; Furthermore, skepticism about results may always be extended to areas not explicitly covered: for example a drug may influence a "secondary endpoint" such as test result (blood pressure, glucose, or cholesterol levels) without having the power to show that it decreases overall mortality or morbidity in a population. </p>
<p>

In managed healthcare systems, evidence-based guideline have been used as a basis for denying insurance coverage for some treatments which are held by the physicians involved to be effective, but of which randomized controlled trials have not yet been published. In some cases, these denials were based upon questions of induction and efficacy as discussed above. For example, if an older generic statin drug has been shown to reduce mortality, is this enough evidence for use of a much more expensive newer statin drug which lowers cholesterol more effectively, but for which mortality reductions have not had time enough to be shown?<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2221%22])">21</ref> If a new, costly therapy that works on tumor blood vessels causes two kinds of cancer to go into remission, is it justified as an expense in a third kind of cancer, before this has specifically been proven?<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2222%22])">22</ref>. Kaiser Permanente did not change its methods of evaluating whether or not new therapies were too "experimental" to be covered, until it was successfully sued twice: once for delaying <link xlink:type="simple" xlink:href="../880/57880.xml">
IVF</link> treatments for two years after the courts determined that scientific evidence of efficacy and safety had reached the "reasonable" stage, and in another case where Kaiser refused to pay for liver transplantation in infants when it had already been shown to be effective in adults, on the basis that use in infants was still "experimental."<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2223%22])">23</ref> Here again the problem of induction plays a key role in arguments.</p>

</sec>
<sec>
<st>
 Evidence-Based Policy </st>

<p>

In his 1996 inaugural speech<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2224%22])">24</ref> as President of the Royal Statistical Society, Adrian Smith held out evidence-based medicine as an exemplar for <it>all</it> public policy. He proposed that Evidence-Based Policy should be established for education, prisons and policing policy and all areas of government.</p>
<p>

The <link>
Users’ Guides to the Medical Literature</link> are a series of journal articles<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2225%22])">25</ref>, and more recently a comprehensive textbook<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%2226%22])">26</ref>, that provide invaluable tips for clinicians wishing to incorporate evidence-based medicine into their practices.</p>

</sec>
<sec>
<st>
See also</st>
<p>

<list>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../833/1274833.xml">
Adverse drug reaction</link></entry>
<entry level="1" type="bullet">

 <work wordnetid="100575741" confidence="0.8">
<treatment wordnetid="100658082" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<care wordnetid="100654885" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<activity wordnetid="100407535" confidence="0.8">
<link xlink:type="simple" xlink:href="../961/1474961.xml">
Adverse effect (medicine)</link></activity>
</psychological_feature>
</act>
</care>
</event>
</treatment>
</work>
</entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../623/3008623.xml">
Clinical trials with surprising outcomes</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../082/1244082.xml">
Consensus (medical)</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../997/66997.xml">
Epidemiology</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../842/1935842.xml">
Evidence-based design</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../861/4796861.xml">
Evidence-based management</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../789/8858789.xml">
Evidence-based pharmacy in developing countries</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../919/2837919.xml">
Evidence based policy</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../308/3289308.xml">
Evidence based practice</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../685/1294685.xml">
Guideline (medical)</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../194/14194.xml">
History of medicine</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../832/13371832.xml">
Hospital accreditation</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../981/1551981.xml">
Medical algorithm</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../783/2245783.xml">
Medical research</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../957/18957.xml">
Medicine</link></entry>
<entry level="1" type="bullet">

 <group_action wordnetid="101080366" confidence="0.8">
<know-how wordnetid="105616786" confidence="0.8">
<intervention wordnetid="101240210" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<method wordnetid="105660268" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<engagement wordnetid="101239064" confidence="0.8">
<link xlink:type="simple" xlink:href="../225/981225.xml">
Nocebo</link></engagement>
</psychological_feature>
</act>
</method>
</event>
</intervention>
</know-how>
</group_action>
</entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../821/142821.xml">
Placebo (origins of technical term)</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../148/12910148.xml">
Policy-based evidence making</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../613/41613.xml">
Quality control</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../884/2636884.xml">
Source criticism</link></entry>
<entry level="1" type="bullet">

 <link xlink:type="simple" xlink:href="../579/2994579.xml">
Systematic review</link></entry>
</list>
</p>

</sec>
<sec>
<st>
 References </st>

<p>

<reflist>
<entry id="1">
 <cite style="font-style:normal">Elstein AS&#32;(2004).&#32;"On the origins and development of evidence-based medicine and medical decision making". <it>Inflamm. Res.</it>&#32;<b>53 Suppl 2</b>: S184–9. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1007%2Fs00011-004-0357-2">
10.1007/s00011-004-0357-2</weblink>. PMID 15338074.</cite>&nbsp;</entry>
<entry id="2">
 <cite style="font-style:normal">Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS&#32;(1996).&#32;"<weblink xlink:type="simple" xlink:href="http://www.bmj.com/cgi/content/full/312/7023/71">
Evidence based medicine: what it is and what it isn't</weblink>". <it>BMJ</it>&#32;<b>312</b>&#32;(7023): 71–2. PMID 8555924.</cite>&nbsp;</entry>
<entry id="3">
 <cite style="font-style:normal">Ezzo J, Bausell B, Moerman DE, Berman B, Hadhazy V&#32;(2001).&#32;"Reviewing the reviews. How strong is the evidence? How clear are the conclusions?". <it>Int J Technol Assess Health Care</it>&#32;<b>17</b>&#32;(4): 457–466. PMID 11758290.</cite>&nbsp;</entry>
<entry id="4">
Committee on the Use of Complementary and Alternative Medicine by the American Public. (2005). <it><weblink xlink:type="simple" xlink:href="http://www.nap.edu/catalog.php?record_id=11182">
Complementary and Alternative Medicine in the United States</weblink></it>. National Academies Press.</entry>
<entry id="5">
 <cite style="font-style:normal">Eddy DM&#32;(2005).&#32;"Evidence-based medicine: a unified approach". <it>Health affairs (Project Hope)</it>&#32;<b>24</b>&#32;(1): 9–17. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1377%2Fhlthaff.24.1.9">
10.1377/hlthaff.24.1.9</weblink>. PMID 15647211.</cite>&nbsp;</entry>
<entry id="6">
<weblink xlink:type="simple" xlink:href="http://www.amazon.com/Evidence-Based-Healthcare-J-Muir-Gray/dp/0443057214">
Amazon.com: Evidence-Based Healthcare: J. A. Muir Gray: Books</weblink></entry>
<entry id="7">
D. Craig Brater and Walter J. Daly (2000), "Clinical pharmacology in the Middle Ages: Principles that presage the 21st century", <it>Clinical Pharmacology &amp; Therapeutics</it> <b>67</b> (5), p. 447-450 [449].</entry>
<entry id="8">
Walter J. Daly and D. Craig Brater (2000), "Medieval contributions to the search for truth in clinical medicine", <it>Perspectives in Biology and Medicine</it> <b>43</b> (4), p. 530–540 [536], <firm wordnetid="108059870" confidence="0.8">
<enterprise wordnetid="108056231" confidence="0.8">
<business wordnetid="108061042" confidence="0.8">
<publisher wordnetid="108062623" confidence="0.8">
<link xlink:type="simple" xlink:href="../095/3726095.xml">
Johns Hopkins University Press</link></publisher>
</business>
</enterprise>
</firm>
.</entry>
<entry id="9">
 <cite style="font-style:normal">Eddy DM&#32;(1990).&#32;"Practice policies: where do they come from?". <it>JAMA</it>&#32;<b>263</b>&#32;(9): 1265, 1269, 1272 passim. PMID 2304243.</cite>&nbsp;</entry>
<entry id="10">
 Guyatt G, Cairns J, Churchill D, et al. [‘Evidence-Based Medicine Working Group’] "Evidence-based medicine. A new approach to teaching the practice of medicine." <it>JAMA</it> 1992;268:2420-5. PMID 1404801</entry>
<entry id="11">
 Oxford Centre for Evidence-based Medicine  <weblink xlink:type="simple" xlink:href="http://www.cebm.net/levels_of_evidence.asp#levels">
Levels of Evidence and Grades of Recommendation</weblink></entry>
<entry id="12">
"<weblink xlink:type="simple" xlink:href="http://www.gradeworkinggroup.org/">
GRADE working group</weblink>".&#32;Retrieved on <link>
2007-09-24</link>.</entry>
<entry id="13">
 <cite style="font-style:normal">Atkins D, Best D, Briss PA, et al&#32;(2004).&#32;"Grading quality of evidence and strength of recommendations". <it>BMJ</it>&#32;<b>328</b>&#32;(7454): 1490. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1136%2Fbmj.328.7454.1490">
10.1136/bmj.328.7454.1490</weblink>. PMID 15205295.</cite>&nbsp;</entry>
<entry id="14">
"<weblink xlink:type="simple" xlink:href="http://www.ahrq.gov/clinic/3rduspstf/ratings.htm">
Task Force Ratings</weblink>".&#32;Retrieved on <link>
2007-09-24</link>.</entry>
<entry id="15">
McQuay, Henry J.;&#32;Moore, R. Andrew&#32;(<link>
1997-05-01</link>).&#32;"<weblink xlink:type="simple" xlink:href="http://www.jr2.ox.ac.uk/bandolier/booth/painpag/NNTstuff/numeric.htm">
Numbers Needed to Treat</weblink>".&#32;  Bandolier.&#32;Retrieved on <link>
2006-06-27</link>.</entry>
<entry id="17">
 <cite style="font-style:normal">Yealy DM, Auble TE, Stone RA, et al&#32;(2005).&#32;"Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial". <it>Ann. Intern. Med.</it>&#32;<b>143</b>&#32;(12): 881–94. PMID 16365469.</cite>&nbsp;</entry>
<entry id="16">
 "Patient Compliance with statins" <it><work wordnetid="104599396" confidence="0.8">
<product wordnetid="104007894" confidence="0.8">
<creation wordnetid="103129123" confidence="0.8">
<artifact wordnetid="100021939" confidence="0.8">
<periodical wordnetid="106593296" confidence="0.8">
<publication wordnetid="106589574" confidence="0.8">
<link xlink:type="simple" xlink:href="../320/4140320.xml">
Bandolier</link></publication>
</periodical>
</artifact>
</creation>
</product>
</work>
 <weblink xlink:type="simple" xlink:href="http://www.jr2.ox.ac.uk/bandolier/booth/cardiac/patcomp.html">
Review</weblink> 2004</it></entry>
<entry id="19">
Rogers, WA&#32;(2004).&#32;"<weblink xlink:type="simple" xlink:href="http://jme.bmj.com/cgi/content/full/30/2/141">
Evidence based medicine and justice: a framework for looking at the impact of EBM upon vulnerable or disadvantaged groups</weblink>".&#32;  J Med Ethics.&#32;Retrieved on <link>
2007-07-12</link>.</entry>
<entry id="18">
 <cite style="font-style:normal">Sackett, DL&#32;(1996).&#32;"<weblink xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8555924&amp;dopt=Abstract">
Evidence based medicine: what it is and what it isn't.</weblink>". <it>BMJ</it>&#32;<b>312</b>&#32;(7023): 71-2.</cite>&nbsp;</entry>
<entry id="21">
http://www.usatoday.com/money/industries/health/drugs/2004-12-26-crestor-cover_x.htm</entry>
<entry id="20">
Friedman, LS;&#32;Richter, ED&#32;(2004).&#32;"<weblink xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14748860&amp;itool=iconabstr">
Relationship between conflicts of interest and research results</weblink>".&#32;  NCBI PubMed.&#32;Retrieved on <link>
2006-06-27</link>.</entry>
<entry id="23">
http://xnet.kp.org/permanentejournal/winter01/HSnewtec.html</entry>
<entry id="22">
http://sfgate.com/cgi-bin/article.cgi?f=/c/a/2006/02/12/MNGD0H7AGT1.DTL&amp;hw=stanford&amp;sn=013&amp;sc=110</entry>
<entry id="25">
Guyatt GH, Rennie D. Users' guides to the medical literature. JAMA. 1993; 270:2096-2097.</entry>
<entry id="24">
 <cite style="font-style:normal">Smith, A.F.M.&#32;(1996).&#32;"Mad cows and ecstasy: chance and choice in an evidence-based society". <it>Journal of the Royal Statistical Association, Series A</it>&#32;<b>159</b>: 367–83.</cite>&nbsp;</entry>
<entry id="26">
Users' Guides to the Medical Literature: A Manual of Evidence-Based Clinical Practice. Guyatt GH, Rennie D, eds. Chicago, IL: AMA Press; 2002.</entry>
</reflist>
</p>

</sec>
<sec>
<st>
 External links </st>
<p>

<list>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.iom.edu/ebm">
http://www.iom.edu/ebm</weblink>-'<institution wordnetid="108053576" confidence="0.8">
<academy wordnetid="108279298" confidence="0.8">
<link xlink:type="simple" xlink:href="../259/431259.xml">
Institute of Medicine</link></academy>
</institution>
 Forum on Evidence Based Medicine' The IOM Roundtable on Evidence-Based Medicine brings together key stakeholders from multiple sectors—patients, health providers, payers, employers, manufacturers, policy makers, and researchers—for cooperative consideration of the ways that evidence can be better developed and applied to drive improvements in the effectiveness and efficiency of medical care in the United States. </entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.cochrane.org/">
Cochrane.org</weblink> - 'The Cochrane Collaboration: The reliable source for evidence in healthcare' (<link xlink:type="simple" xlink:href="../579/2994579.xml">
systematic review</link>s of the effects of health care interventions), <link xlink:type="simple" xlink:href="../766/240766.xml">
Cochrane Library</link> Major source of rigorous EBM evaluations. </entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.ahrq.gov/clinic/uspstfix.htm">
AHRQ.gov</weblink> - 'U.S. Preventive Services Task Force (USPSTF)', Agency for Health Care Research and Quality. Major source of EBM evaluations </entry>
<entry level="1" type="bullet">

 '<weblink xlink:type="simple" xlink:href="http://www.acc.org/qualityandscience/quality/evidence.htm">
What Is Evidence-Based Medicine?</weblink>' - <association wordnetid="108049401" confidence="0.8">
<institution wordnetid="108053576" confidence="0.8">
<link xlink:type="simple" xlink:href="../769/1358769.xml">
American College of Cardiology</link></institution>
</association>
</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.cmaj.ca/cgi/content/full/163/7/837">
CMAJ.ca</weblink> - 'Evidence-based medicine: a commentary on common criticisms', Dr. Sharon E. Straus, Dr. Finlay A. McAlister, <it><work wordnetid="104599396" confidence="0.8">
<product wordnetid="104007894" confidence="0.8">
<creation wordnetid="103129123" confidence="0.8">
<artifact wordnetid="100021939" confidence="0.8">
<periodical wordnetid="106593296" confidence="0.8">
<publication wordnetid="106589574" confidence="0.8">
<link xlink:type="simple" xlink:href="../611/773611.xml">
Canadian Medical Association Journal</link></publication>
</periodical>
</artifact>
</creation>
</product>
</work>
</it>, Vol 163, No 7, pp 837 - 841 (<link xlink:type="simple" xlink:href="../347/22347.xml">
October 3</link>, <link xlink:type="simple" xlink:href="../548/34548.xml">
2000</link>)</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.mja.com.au/public/issues/174_05_050301/craig/craig.html">
MJA.com.au</weblink> - 'Evidence-based medicine: useful tools for decision making', Jonathan C. Craig, Les M. Irwig, Martin R. Stockler, <it><link xlink:type="simple" xlink:href="../720/15110720.xml">
Medical Journal of Australia</link></it>, vol 174, p 248-253 (2001) </entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ije/vol4n1/evidence.xml">
ISPUB.com</weblink> - 'Evidence-biased medicine: Intention-to-treat analysis less conservative?'. <it>The Internet Journal of Epidemiology</it>. 4(1). 2007</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.gpnotebook.co.uk/simplepage.cfm?ID=-1596981199">
GPNoteBook.co.uk</weblink> - 'Evidence-based medicine (EBM)', General Practice Notebook Free content </entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.jr2.ox.ac.uk/bandolier/">
JR2.ox.ac.uk</weblink> - 'Bandolier: Evidence-based thinking about health care', <it><work wordnetid="104599396" confidence="0.8">
<product wordnetid="104007894" confidence="0.8">
<creation wordnetid="103129123" confidence="0.8">
<artifact wordnetid="100021939" confidence="0.8">
<periodical wordnetid="106593296" confidence="0.8">
<publication wordnetid="106589574" confidence="0.8">
<link xlink:type="simple" xlink:href="../320/4140320.xml">
Bandolier (journal)</link></publication>
</periodical>
</artifact>
</creation>
</product>
</work>
</it> Free reviews online </entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.shef.ac.uk/~scharr/ir/netting/">
SHEF.ac.uk</weblink> - 'Netting the Evidence: A ScHARR Introduction to Evidence Based Practice on the Internet' (resource directory), <university wordnetid="108286163" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../417/310417.xml">
University of Sheffield</link></university>
 Extensive bibliographies and links to online articles</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.tripdatabase.com">
TRIP Database</weblink> - 'TRIP Database - EBM search engine' (resource directory), TRIP Knowledge Service. Free. </entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://bmj.com/cgi/content/full/312/7023/71">
BMJ.com</weblink> - 'Evidence based medicine: what it is and what it isn't: It's about integrating individual clinical expertise and the best external evidence', (editorial) <it><periodical wordnetid="106593296" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../927/541927.xml">
British Medical Journal</link></periodical>
</it>, vol 312, p 71-72 (<link xlink:type="simple" xlink:href="../191/16191.xml">
January 13</link>, <link xlink:type="simple" xlink:href="../636/34636.xml">
1996</link>)</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.bmj.com/cgi/content/full/310/6987/1126">
BMJ.com</weblink> - 'Evidence based medicine: Socratic dissent', (Education and debate) <it><periodical wordnetid="106593296" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../927/541927.xml">
British Medical Journal</link></periodical>
</it>, vol 310, p 1126-1127 (<link xlink:type="simple" xlink:href="../416/1416.xml">
April 29</link>, <link xlink:type="simple" xlink:href="../658/34658.xml">
1995</link>)</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.cebm.net/index.asp">
CEBM.net</weblink> - <village wordnetid="108672738" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../308/22308.xml">
Oxford</link></village>
 Centre for Evidence-Based Medicine (UK) Some free content </entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://bmj.bmjjournals.com/cgi/content/full/327/7429/1459">
BMJ.BMJjournals.com</weblink> - 'Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials', Gordon C S Smith, Jill P Pell, <it><periodical wordnetid="106593296" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../927/541927.xml">
British Medical Journal</link></periodical>
</it>, Vol 327, pp 1459-1461 (<link xlink:type="simple" xlink:href="../849/8849.xml">
20 December</link> <link xlink:type="simple" xlink:href="../163/36163.xml">
2003</link>) (Classic argument that situations still exist where RCTs are unnecessary.)</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.eboncall.org/">
EBOnCall.org</weblink> - 'Evidence compendia' (evidence-based summaries of 38 on-call medical conditions), Evidence-Based On-Call (EBOC) Free </entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.professorebm.com/">
ProfessorEBM</weblink> – ‘Interactive teaching modules, with evidence-based summaries of internal medicine topics.  Free content and links to classic journal articles.</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.dmoz.org/Health/Medicine/Evidence_Based_Medicine//">
Evidence-based medicine</weblink> at the <work wordnetid="100575741" confidence="0.8">
<possession wordnetid="100032613" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<company wordnetid="108058098" confidence="0.8">
<undertaking wordnetid="100795720" confidence="0.8">
<property wordnetid="113244109" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<activity wordnetid="100407535" confidence="0.8">
<subsidiary_company wordnetid="108003935" confidence="0.8">
<institution wordnetid="108053576" confidence="0.8">
<link xlink:type="simple" xlink:href="../501/18949501.xml">
Open Directory Project</link></institution>
</subsidiary_company>
</activity>
</psychological_feature>
</act>
</property>
</undertaking>
</company>
</event>
</possession>
</work>
</entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.dbskeptic.com/2008/08/17/the-limits-of-evidence-based-medicine/">
DBSkeptic.com</weblink> The limits of evidence-based medicine</entry>
</list>
</p>

<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";" class="navbox-title">
<link xlink:type="simple" xlink:href="../783/2245783.xml">
Biomedical research</link>: <link xlink:type="simple" xlink:href="../829/2944829.xml">
Study design</link>s / <link xlink:type="simple" xlink:href="../541/9541.xml">
Design of experiments</link></header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";;" class="navbox-group">
Overview</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../717/241717.xml">
Clinical trial</link>&nbsp;·  <link xlink:type="simple" xlink:href="../391/2193391.xml">
Clinical trial protocol</link>&nbsp;·  <link xlink:type="simple" xlink:href="../487/2196487.xml">
Clinical trial management</link>&nbsp;·  <link xlink:type="simple" xlink:href="../281/2312281.xml">
Academic clinical trials</link>&nbsp;·  <link xlink:type="simple" xlink:href="../829/2944829.xml">
Study design</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
<link xlink:type="simple" xlink:href="../288/1640288.xml">
Controlled study</link>
(<link xlink:type="simple" xlink:href="../013/10013.xml#xpointer(//*[./st=%22Qualification+of+evidence%22])">
EBM I to II-1; A to B</link>)</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../180/163180.xml">
Randomized controlled trial</link> (<link xlink:type="simple" xlink:href="../248/277248.xml">
Blind experiment</link>, <link xlink:type="simple" xlink:href="../515/1550515.xml">
Open-label trial</link>)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
<idea wordnetid="105833840" confidence="0.8">
<concept wordnetid="105835747" confidence="0.8">
<category wordnetid="105838765" confidence="0.8">
<type wordnetid="105840188" confidence="0.8">
<kind wordnetid="105839024" confidence="0.8">
<link xlink:type="simple" xlink:href="../483/6326483.xml">
Observational study</link></kind>
</type>
</category>
</concept>
</idea>

(<link xlink:type="simple" xlink:href="../013/10013.xml#xpointer(//*[./st=%22Qualification+of+evidence%22])">
EBM II-2 to II-3; B to C</link>)</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<know-how wordnetid="105616786" confidence="0.8">
<method wordnetid="105660268" confidence="0.8">
<link xlink:type="simple" xlink:href="../627/1557627.xml">
Cross-sectional study</link></method>
</know-how>
 vs. <idea wordnetid="105833840" confidence="0.8">
<concept wordnetid="105835747" confidence="0.8">
<category wordnetid="105838765" confidence="0.8">
<know-how wordnetid="105616786" confidence="0.8">
<method wordnetid="105660268" confidence="0.8">
<type wordnetid="105840188" confidence="0.8">
<kind wordnetid="105839024" confidence="0.8">
<link xlink:type="simple" xlink:href="../623/1557623.xml">
Longitudinal study</link></kind>
</type>
</method>
</know-how>
</category>
</concept>
</idea>
<p>

<idea wordnetid="105833840" confidence="0.8">
<concept wordnetid="105835747" confidence="0.8">
<category wordnetid="105838765" confidence="0.8">
<know-how wordnetid="105616786" confidence="0.8">
<method wordnetid="105660268" confidence="0.8">
<type wordnetid="105840188" confidence="0.8">
<kind wordnetid="105839024" confidence="0.8">
<link xlink:type="simple" xlink:href="../271/397271.xml">
Cohort study</link></kind>
</type>
</method>
</know-how>
</category>
</concept>
</idea>
 (<link xlink:type="simple" xlink:href="../844/14905844.xml">
Retrospective cohort study</link>, <link xlink:type="simple" xlink:href="../025/16107025.xml">
Prospective cohort study</link>)</p>
<p>

<link xlink:type="simple" xlink:href="../661/788661.xml">
Case-control study</link> (<link xlink:type="simple" xlink:href="../860/2946860.xml">
Nested case-control study</link>)</p>
<p>

<know-how wordnetid="105616786" confidence="0.8">
<method wordnetid="105660268" confidence="0.8">
<link xlink:type="simple" xlink:href="../159/11832159.xml">
Case series</link></method>
</know-how>
&nbsp;·  <link xlink:type="simple" xlink:href="../471/304471.xml">
Case study</link>/<link xlink:type="simple" xlink:href="../729/4585729.xml">
Case report</link></p>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
<link xlink:type="simple" xlink:href="../997/66997.xml">
Epidemiology</link>/
<link xlink:type="simple" xlink:href="../767/265767.xml">
methods</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<it>Occurrence:</it> <link xlink:type="simple" xlink:href="../008/167008.xml">
Incidence</link> (<link xlink:type="simple" xlink:href="../897/5075897.xml">
Cumulative incidence</link>)&nbsp;·  <link xlink:type="simple" xlink:href="../688/126688.xml">
Prevalence</link> (<link xlink:type="simple" xlink:href="../112/9459112.xml">
Point prevalence</link>, <link xlink:type="simple" xlink:href="../191/9459191.xml">
Period prevalence</link>)<p>

<it><link xlink:type="simple" xlink:href="../313/569313.xml">
Association</link>:</it> <link xlink:type="simple" xlink:href="../159/2622159.xml">
Relative risk</link>&nbsp;·  <link xlink:type="simple" xlink:href="../880/406880.xml">
Odds ratio</link>&nbsp;·  <link xlink:type="simple" xlink:href="../769/265769.xml">
Hazard ratio</link>&nbsp;·  <link xlink:type="simple" xlink:href="../923/7735923.xml">
Attributable risk</link></p>
<p>

<it>other:</it> <link xlink:type="simple" xlink:href="../929/406929.xml">
Virulence</link>&nbsp;·  <link xlink:type="simple" xlink:href="../235/2945235.xml">
Infectivity</link>&nbsp;·  <link xlink:type="simple" xlink:href="../305/191305.xml">
Mortality rate</link>&nbsp;·  <link xlink:type="simple" xlink:href="../018/196018.xml">
Morbidity</link>&nbsp;·  <link xlink:type="simple" xlink:href="../385/3560385.xml">
Case fatality</link>&nbsp;·  <link xlink:type="simple" xlink:href="../330/5599330.xml">
Sensitivity and specificity</link></p>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
Trial/test types</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../188/15188.xml">
In vitro</link>/<link xlink:type="simple" xlink:href="../187/15187.xml">
In vivo</link>&nbsp;·  <technique wordnetid="105665146" confidence="0.8">
<know-how wordnetid="105616786" confidence="0.8">
<method wordnetid="105660268" confidence="0.8">
<right wordnetid="105174653" confidence="0.8">
<link xlink:type="simple" xlink:href="../596/175596.xml">
Animal testing</link></right>
</method>
</know-how>
</technique>
&nbsp;·  <know-how wordnetid="105616786" confidence="0.8">
<method wordnetid="105660268" confidence="0.8">
<link xlink:type="simple" xlink:href="../113/12005113.xml">
First-in-man study</link></method>
</know-how>
&nbsp;·  <link xlink:type="simple" xlink:href="../461/2221461.xml">
Multicenter trial</link>&nbsp;·  <link xlink:type="simple" xlink:href="../065/18931065.xml">
Seeding trial</link>&nbsp;·  <link xlink:type="simple" xlink:href="../730/1065730.xml">
Vaccine trial</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";;" class="navbox-group">
<link xlink:type="simple" xlink:href="../813/17410813.xml">
Analysis of clinical trials</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<know-how wordnetid="105616786" confidence="0.8">
<method wordnetid="105660268" confidence="0.8">
<link xlink:type="simple" xlink:href="../316/2244316.xml">
Risk-benefit analysis</link></method>
</know-how>
</col>
</row>
<row style="height:2px;">

</row>
<row>
<col colspan="2" style=";" class="navbox-abovebelow">
<b>
Clinical research|Category</b>&nbsp;&amp;bull; <b><link xlink:type="simple" xlink:href="../485/19627485.xml">
Glossary</link></b>&nbsp;&amp;bull; <b><link xlink:type="simple" xlink:href="../563/19645563.xml">
List of topics</link></b></col>
</row>
</table>
</col>
</row>
</table>
</p>



</sec>
</bdy>
</article>
